Title: Staphylococcus saprophyticus: Which beta-lactam? - ScienceDirect
Headings: Staphylococcus saprophyticus
: Which beta-lactam?

International Journal of Infectious Diseases
Short Communication
Staphylococcus saprophyticus: Which beta-lactam?
Highlights
Abstract
Background
Methods
Results
Conclusions
Keywords
Introduction
Methods
Results
Discussion
Conflict of interest/funding
References

Content: Discussion
In the literature, the prevalence of MSSS in UTI varies from 3% to 42%, depending on factors such as patient age ( Hur et al., 2016, Lo et al., 2015 ). Complications of UTIs due to MSSS such as pyelonephritis, nephrolithiasis, and in the case of male patients, urethritis, epididymitis, and prostatitis, are uncommonly reported ( Chen, 2014, Hovelius and Mårdh, 1984, Raz et al., 2005 ). The high proportion of pyelonephritis (33.3%) that was recorded in the present study suggests that this clinical feature should be considered. MSSS is often considered as usually susceptible to most antibiotics ( Chen, 2014 ). However, some natural resistance to the antibiotics commonly used for empirical antimicrobial therapy in UTIs, such as cefixime and fosfomycin trometamol, is known for this pathogen. In this study, 60% of cystitis and 25% of pyelonephritis due to MSSS was treated with an ineffective empirical antimicrobial therapy (cefixime, fosfomycin, or amoxicillin). Of the 56 urine samples with Gram-positive cocci observed on direct examination, 50% were treated with an empirical antibiotic therapy that is ineffective against MSSS, underlining the fact that despite suggestive results on direct examination, the hypothesis of MSSS resistance had not been taken into account for empirical treatment.